Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
56.7M
-
Shares change
-
+73.8K
-
Total reported value, excl. options
-
$946M
-
Value change
-
-$53.3M
-
Put/Call ratio
-
0.11
-
Number of buys
-
82
-
Number of sells
-
-75
-
Price
-
$16.68
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q3 2023
195 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q3 2023.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.7M shares
of 61.4M outstanding shares and own 92.39% of the company stock.
Largest 10 shareholders include BVF INC/IL (5.74M shares), FARALLON CAPITAL MANAGEMENT LLC (5.45M shares), RTW INVESTMENTS, LP (5.42M shares), BlackRock Inc. (5.23M shares), STATE STREET CORP (3.94M shares), VANGUARD GROUP INC (3.23M shares), JOHNSON & JOHNSON (2.45M shares), Kynam Capital Management, LP (1.82M shares), COWEN AND COMPANY, LLC (1.66M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.18M shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.